Introducing the New Definition and Diagnostic Criteria of Disseminated Intravascular Coagulation Released by the International Society on Thrombosis and Haemostasis in 2025.

IF 4.1 2区 医学 Q2 HEMATOLOGY
Toshiaki Iba, Cheryl L Maier, Ecaterina Scarlatescu, Jerrold H Levy
{"title":"Introducing the New Definition and Diagnostic Criteria of Disseminated Intravascular Coagulation Released by the International Society on Thrombosis and Haemostasis in 2025.","authors":"Toshiaki Iba, Cheryl L Maier, Ecaterina Scarlatescu, Jerrold H Levy","doi":"10.1055/a-2675-6068","DOIUrl":null,"url":null,"abstract":"<p><p>In 2025, the International Society on Thrombosis and Haemostasis (ISTH) released updated definitions and diagnostic criteria for disseminated intravascular coagulation (DIC), reflecting advances in understanding its pathophysiology. DIC is now defined as an acquired, life-threatening condition involving systemic coagulation activation, impaired fibrinolysis, and endothelial injury. The revised framework emphasizes the condition's dynamic nature, progressing from preclinical abnormalities to overt clinical manifestations such as bleeding and organ dysfunction. A major innovation in the 2025 update is the phase-based classification of DIC: Pre-DIC, early-phase DIC, and overt DIC. Early-phase DIC-also referred to as subclinical or compensated DIC-is characterized by laboratory abnormalities preceding clinical symptoms. Overt DIC represents the advanced stage with clear evidence of coagulopathy and organ failure. Importantly, the new criteria are tailored to the underlying disease, such as sepsis, trauma, or malignancy. For example, the sepsis-induced coagulopathy score is now acknowledged as a tool for detecting early-phase DIC in septic patients. The overt DIC scoring system has been refined, including revised D-dimer thresholds: Levels >3× and >7 × , the upper normal limit now corresponds to 2 and 3 points, respectively. Platelet count, prothrombin time-international normalized ratio, and fibrinogen levels remain key indicators. The criteria also classify DIC into thrombotic and hemorrhagic phenotypes. Thrombotic DIC is marked by microvascular thrombosis and organ dysfunction, while hemorrhagic DIC is characterized by bleeding due to consumption of coagulation factors. By introducing clearer definitions and individualized approaches, these updates aim to enable earlier diagnosis and more effective management of DIC across clinical contexts.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in thrombosis and hemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2675-6068","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In 2025, the International Society on Thrombosis and Haemostasis (ISTH) released updated definitions and diagnostic criteria for disseminated intravascular coagulation (DIC), reflecting advances in understanding its pathophysiology. DIC is now defined as an acquired, life-threatening condition involving systemic coagulation activation, impaired fibrinolysis, and endothelial injury. The revised framework emphasizes the condition's dynamic nature, progressing from preclinical abnormalities to overt clinical manifestations such as bleeding and organ dysfunction. A major innovation in the 2025 update is the phase-based classification of DIC: Pre-DIC, early-phase DIC, and overt DIC. Early-phase DIC-also referred to as subclinical or compensated DIC-is characterized by laboratory abnormalities preceding clinical symptoms. Overt DIC represents the advanced stage with clear evidence of coagulopathy and organ failure. Importantly, the new criteria are tailored to the underlying disease, such as sepsis, trauma, or malignancy. For example, the sepsis-induced coagulopathy score is now acknowledged as a tool for detecting early-phase DIC in septic patients. The overt DIC scoring system has been refined, including revised D-dimer thresholds: Levels >3× and >7 × , the upper normal limit now corresponds to 2 and 3 points, respectively. Platelet count, prothrombin time-international normalized ratio, and fibrinogen levels remain key indicators. The criteria also classify DIC into thrombotic and hemorrhagic phenotypes. Thrombotic DIC is marked by microvascular thrombosis and organ dysfunction, while hemorrhagic DIC is characterized by bleeding due to consumption of coagulation factors. By introducing clearer definitions and individualized approaches, these updates aim to enable earlier diagnosis and more effective management of DIC across clinical contexts.

介绍国际血栓与止血学会2025年发布的弥散性血管内凝血的新定义和诊断标准。
2025年,国际血栓与止血学会(ISTH)发布了弥散性血管内凝血(DIC)的最新定义和诊断标准,反映了对其病理生理学的理解取得了进展。DIC现在被定义为一种获得性的、危及生命的疾病,涉及全身凝血激活、纤维蛋白溶解受损和内皮损伤。修订后的框架强调了病情的动态性,从临床前异常发展到明显的临床表现,如出血和器官功能障碍。2025年更新的一个主要创新是DIC的阶段分类:Pre-DIC,早期DIC和显性DIC。早期dic也被称为亚临床或代偿性dic,其特征是在临床症状出现之前出现实验室异常。明显的DIC表现为晚期凝血功能障碍和器官衰竭。重要的是,新标准是针对潜在疾病,如败血症、创伤或恶性肿瘤量身定制的。例如,脓毒症诱导的凝血功能评分现在被认为是一种检测脓毒症患者早期DIC的工具。显性DIC评分系统已被完善,包括修订的d -二聚体阈值:水平bbb3x和> 7x,正常上限现在分别对应2和3分。血小板计数、凝血酶原时间-国际标准化比率和纤维蛋白原水平仍然是关键指标。该标准还将DIC分为血栓性和出血性表型。血栓性DIC的特征是微血管血栓形成和器官功能障碍,而出血性DIC的特征是由于凝血因子的消耗而出血。通过引入更清晰的定义和个性化的方法,这些更新旨在实现DIC的早期诊断和更有效的临床管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Seminars in thrombosis and hemostasis
Seminars in thrombosis and hemostasis 医学-外周血管病
CiteScore
8.80
自引率
21.10%
发文量
132
审稿时长
6-12 weeks
期刊介绍: Seminars in Thrombosis and Hemostasis is a topic driven review journal that focuses on all issues relating to hemostatic and thrombotic disorders. As one of the premiere review journals in the field, Seminars in Thrombosis and Hemostasis serves as a comprehensive forum for important advances in clinical and laboratory diagnosis and therapeutic interventions. The journal also publishes peer reviewed original research papers. Seminars offers an informed perspective on today''s pivotal issues, including hemophilia A & B, thrombophilia, gene therapy, venous and arterial thrombosis, von Willebrand disease, vascular disorders and thromboembolic diseases. Attention is also given to the latest developments in pharmaceutical drugs along with treatment and current management techniques. The journal also frequently publishes sponsored supplements to further highlight emerging trends in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信